Reactions from Apollo, Blackstone, The Carlyle Group and Hamilton Lane on Trump's executive order allowing 401(k) investors ...

In Q2 2025, the global pharma sector experienced a decline in M&A activity, with deals worth $32.9 billion, down 11.6% from Q1. Deal volume fell 12.8% to 130. Oncology led with 51 deals. Discover key ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, Tax Shelters, Insurance bonds. Momentum returns as biotech enters next phase ...

Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-pe ...

Sanofi’s latest earnings call reflects a positive outlook for the company, marked by strong sales growth, strategic acquisitions, and a commitment to sustainability. Despite some challenges, such as ...